FDA approves medicine for treatment of deep vein thrombosis

Share this article:
FDA approves medicine for treatment of deep vein thrombosis
FDA approves medicine for treatment of deep vein thrombosis

The Food and Drug Administration has approved Janssen Pharmaceuticals, Inc.'s Xarelto (rivaroxaban ). Xarelto is intended for the treatment of deep vein thrombosis (DVT). If all or part of a DVT breaks off, it can travel to and lodge in the lungs, and can lead to potentially life-threatening consequences.


Share this article:

More in Products

Bertlesmann buys Relias Learning

Bertelsmann, a media company based in Germany, said last week it is buying Relias Learning from its current owners, Vista Equity Partners and LLR Partners.

Acuity Brands introduces LED collection

Acuity Brands introduces LED collection

Acuity Brands says its new CanoeTM LED Pendant and Sconce Collection from Winona Lighting® can meet the needs of designers in unique spaces.

SwimEx debuts Triton Pool

SwimEx debuts Triton Pool

SwimEx Inc. has announced the Triton, the newest member of its line of fitness and therapy pools. It is available for the commercial and residential markets.